Protheragen, Inc. and Clinical Service Center (CSC) have officially signed a strategic cooperation agreement. The two parties will leverage the “Project + Platform” collaborative model, integrating Protheragen’s strengths in innovative drug incubation, cross-border capital connection, and global BD networks with CSC’s expertise in clinical trial operations, medical affairs, data statistics, regulatory affairs, and China-US & international filing, to build a cross-border, mutually empowering ecosystem for drug development and capital collaboration.
Against the backdrop of increasingly active cross-border flows of global pharmaceutical innovation, the strategic partnership between Protheragen and CSC achieves a precise match between clinical research service resources and cross-border capital connection capabilities.
Protheragen, headquartered in New York, USA, is a global pharmaceutical R&D incubation and cross-border BD enablement platform. Its business covers three core areas: project incubation, equity investment and cross-border BD consulting. With over 18 years of industry resource accumulation, Protheragen has extensive experience in cross-border deal facilitation, project financing, and in/out-licensing.
Clinical Service Center (CSC) is a full-service clinical CRO offering clinical trial operations, regulatory affairs, medical writing, biostatistics and data management, pharmacovigilance, quality assurance, and training consulting. CSC has multi-center, multinational clinical trial operation capabilities. With a professional service team of over 1,000 employees, CSC has served nearly 1,000 clinical projects, with innovative drug projects accounting for more than 80%. Its core team brings more than 20 years of experience from multinational corporations.
Under the agreement, the two parties have established the “Project + Platform” collaborative model. Protheragen will leverage its global BD network and capital connection advantages to help CSC expand overseas client resources and guide international biopharmaceutical companies to conduct clinical research projects in China. In addition, Protheragen will provide overseas financing matchmaking services for CSC’s clinical projects. CSC will contribute its full-process clinical trial operation and China-US & international filing capabilities to deliver high-quality clinical research services for overseas projects referred by Protheragen.
The partnership organically couples Protheragen’s cross-border BD and capital enablement capabilities with CSC’s professional clinical CRO service capabilities, creating a full-chain synergy from “project introduction” to “capital connection” to “clinical execution.” Together, the two parties aim to build an open, win-win, and sustainable cross-border ecosystem for drug development and capital collaboration.
Protheragen's business is growing rapidly after founded in New York. Our business has evolved from the initial cross-border BD consulting service to encompass segments in equity investment and project incubation.
 |
Protheragen Inc. |
 |
Quick Links |
